[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 40
1. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M: Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant; 2010 Feb;16(2):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents.
  • We examined the role of hematopoietic stem cell transplantation (HSCT) for patients aged< or =18 years with refractory or recurrent Burkitt (n=41), lymphoblastic (n=53), diffuse large B cell (DLBCL; n=52), and anaplastic large cell lymphoma (n=36), receiving autologous (n=90) or allogeneic (n=92; 43 matched sibling and 49 unrelated donor) HSCT in 1990-2005.
  • Allogeneic donor HSCT was more likely to use irradiation-containing conditioning regimens, bone marrow (BM) stem cells, be performed in more recent years, and for lymphoblastic lymphoma.
  • After adjusting for disease status, 5-year EFS were similar after allogeneic and autologous HSCT for DLBCL (50% vs 52%), Burkitt (31% vs 27%), and anaplastic large cell lymphoma (46% vs 35%).
  • However, EFS was higher for lymphoblastic lymphoma, after allogeneic HSCT (40% vs 4%; P < .01).
  • Predictors of EFS for progressive or recurrent disease after HSCT included disease status at HSCT and use of allogeneic donor for lymphoblastic lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix [10553263.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):897-903 [19139435.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):965-8 [11298592.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2390-6 [11331317.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cytotherapy. 2002;4(3):253-8 [12194721.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2938-42 [1450419.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2003-6 [8471762.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):353-9 [7599558.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2921-30 [9376572.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):70-6 [15368550.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):176-82 [16611309.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):787-94 [16932891.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):188-92 [18428432.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • (PMID = 19800015.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-14; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / CA076518-14; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217814; NLM/ PMC2911354
  •  go-up   go-down


2. Sakamoto K, Nakasone H, Togashi Y, Sakata S, Tsuyama N, Baba S, Dobashi A, Asaka R, Tsai CC, Chuang SS, Izutsu K, Kanda Y, Takeuchi K: ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. Int J Hematol; 2016 Apr;103(4):399-408
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.
  • Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+LBCL) is a rare, aggressive B-cell lymphoma with ALK fusion genes.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Receptor Protein-Tyrosine Kinases / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2013 May;37(5):780-6 [23588372.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4211-6 [19636007.001]
  • [Cites] PLoS One. 2012;7(2):e31323 [22347464.001]
  • [Cites] Eur J Haematol. 2014 Mar;92(3):268-70 [24330038.001]
  • [Cites] Hematol Oncol. 2014 Dec;32(4):221-4 [24470379.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Int J Clin Exp Pathol. 2009 Mar 13;2(6):508-18 [19636398.001]
  • [Cites] Haematologica. 2011 Feb;96(2):343-6 [21109691.001]
  • [Cites] Haematologica. 2010 Mar;95(3):509-13 [20207848.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2014 Mar;62(3):191-4 [23345154.001]
  • [Cites] Thyroid. 2012 Nov;22(11):1153-9 [23050789.001]
  • [Cites] Leukemia. 2010 Jun;24(6):1197-200 [20428197.001]
  • [Cites] J Hematol Oncol. 2009 Feb 27;2:11 [19250532.001]
  • [Cites] Int J Clin Exp Pathol. 2013 Oct 15;6(11):2631-5 [24228132.001]
  • [Cites] Eur J Haematol. 2013 Mar;90(3):261 [23171433.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Int J Clin Exp Med. 2015 May 15;8(5):6977-85 [26221234.001]
  • [Cites] J Natl Cancer Inst. 2014 Feb;106(2):djt378 [24491302.001]
  • [Cites] Indian J Pathol Microbiol. 2015 Apr-Jun;58(2):241-5 [25885146.001]
  • [Cites] Clin Cancer Res. 2012 Sep 1;18(17 ):4682-90 [22912387.001]
  • [Cites] Mol Cancer Res. 2009 Sep;7(9):1466-76 [19737969.001]
  • [Cites] N Engl J Med. 2011 Feb 24;364(8):775-6 [21345110.001]
  • [Cites] Pathol Res Pract. 2011 Sep 15;207(9):587-91 [21855232.001]
  • [Cites] Pathol Int. 2014 Jun;64(6):292-4 [24965113.001]
  • [Cites] J Clin Pathol. 2015 Jun;68(6):496-8 [25720769.001]
  • [Cites] Cancer. 2012 Sep 15;118(18):4427-36 [22252991.001]
  • [Cites] Cancer Res. 2015 Jun 1;75(11):2146-50 [26032424.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Bone Marrow Transplant. 2013 Mar;48(3):452-8 [23208313.001]
  • [Cites] N Engl J Med. 2010 Oct 28;363(18):1693-703 [20979469.001]
  • [Cites] Bone Marrow Transplant. 2011 Jun;46(6):904-5 [20818450.001]
  • [Cites] Am J Surg Pathol. 2011 Jan;35(1):135-44 [21164297.001]
  • [Cites] Int J Hematol. 2014 Feb;99(2):202-7 [24307515.001]
  • [Cites] Diagn Pathol. 2013 Sep 13;8:147 [24034896.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6071-82 [15208656.001]
  • [Cites] N Engl J Med. 2010 Oct 28;363(18):1727-33 [20979472.001]
  • [Cites] Haematologica. 2011 Mar;96(3):464-7 [21134980.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2965-8 [18660380.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Lancet Oncol. 2013 Jun;14(7):590-8 [23639470.001]
  • (PMID = 26781614.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Keywords] NOTNLM ; Anaplastic lymphoma kinase / Anaplastic lymphoma kinase-positive large B-cell lymphoma / EML4-ALK / Fusion partner / Immunohistochemistry
  •  go-up   go-down


3. Sakai T, Tamura S, Miyoshi T, Nesumi N, Nagai K, Oshima K: Development of myeloid sarcoma after long-term methotrexate use for rheumatoid arthritis. Int J Hematol; 2014 Apr;99(4):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myeloid sarcoma (MS) in the complete absence of bone marrow disease is an extremely rare phenomenon.
  • She was initially diagnosed with ALK-negative anaplastic large cell lymphoma.
  • Although the lesions were partially reduced in size following treatment for lymphoma, complete response (CR) was obtained only after AML chemotherapy.
  • An early diagnosis and adequate therapy may be important for improving survival outcomes in MS.
  • This report demonstrates that CD68 staining is important for the differential diagnosis of MS and lymphoma.


Advertisement
4. Lawrenz J, Tomal J, Towne J, Johnson B, Rieger B: ALK+ Anaplastic Large Cell Lymphoma With Bladder Involvement Presenting as Fever of Unknown Origin: A Case Report and Literature Review. World J Oncol; 2013 Apr;4(2):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK+ Anaplastic Large Cell Lymphoma With Bladder Involvement Presenting as Fever of Unknown Origin: A Case Report and Literature Review.
  • Anaplastic large cell lymphoma (ALCL) is a rare malignant tumor normally originating in lymph nodes, though it can occur in extranodal sites.
  • We report a 59-year-old man with anaplastic lymphoma kinase (ALK) positive ALCL involving the bladder diagnosed post-mortem who presented with fever of unknown origin.
  • Bone marrow biopsy also was negative for malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2008 Apr;58(4):249-52 [18324919.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):369-73 [16273198.001]
  • [Cites] Croat Med J. 2008 Oct;49(5):660-8 [18925700.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:1-30 [13734791.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Leuk Lymphoma. 2005 Jun;46(6):873-7 [16019532.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1324-33 [9351570.001]
  • [Cites] J Blood Med. 2011;2:119-29 [22287871.001]
  • [Cites] ScientificWorldJournal. 2008 Mar 25;8:342-5 [18379710.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Acta Cytol. 2008 Jan-Feb;52(1):83-6 [18323280.001]
  • [Cites] Haematologica. 2009 Jul;94(7):897-900 [19570751.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):841-3 [15160969.001]
  • [Cites] Adv Hematol. 2010;:345053 [21331150.001]
  • (PMID = 29147338.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Bladder / Fever of unknown origin / Macrophage activation syndrome
  •  go-up   go-down


5. Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F: The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist; 2016 Jan;21(1):102-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
  • BACKGROUND: On October 25, 2012, a conditional marketing authorization valid throughout the European Union (EU) was issued for brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) and for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
  • For HL, the indication is restricted to treatment after autologous stem cell transplantation (ASCT) or after at least two previous therapies when ASCT or multiagent chemotherapy is not a treatment option.
  • Binding of the ADC to CD30 on the cell surface initiates internalization of the MMAE-CD30 complex, followed by proteolytic cleavage that releases MMAE.
  • IMPLICATIONS FOR PRACTICE: Brentuximab vedotin was approved in the European Union for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
  • For Hodgkin lymphoma, brentuximab vedotin should only be used after autologous stem cell transplantation or following at least two prior therapies when transplantation or multiagent chemotherapy is not a treatment option.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hodgkin Disease / drug therapy. Immunoconjugates / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©AlphaMed Press.
  • [Cites] Ann Oncol. 1993;4 Suppl 1:7-13 [8101727.001]
  • [Cites] Cell. 1993 Jul 2;73(7):1349-60 [8391931.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3378-404 [7780126.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):13-9 [10076716.001]
  • [Cites] Clin Immunol. 1999 Feb;90(2):157-64 [10080826.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):625-33 [15737986.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] BMC Genomics. 2006;7:263 [17052335.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72 [17084370.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:326-33 [19074105.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:497-506 [20008235.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):888-97 [20086002.001]
  • [Cites] J Clin Oncol. 2011 Nov 10;29(32):4234-42 [21990399.001]
  • [Cites] J Clin Oncol. 2012 Jun 20;30(18):2183-9 [22454421.001]
  • [Cites] J Clin Oncol. 2012 Jun 20;30(18):2190-6 [22614995.001]
  • [Cites] Oncologist. 2012;17(8):1073-80 [22855426.001]
  • [Cites] J Clin Oncol. 2012 Nov 10;30(32):3939-46 [23045585.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):673-9 [13130314.001]
  • [Cites] Blood. 1990 Jul 15;76(2):424-31 [1973361.001]
  • (PMID = 26621039.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 7XL5ISS668 / brentuximab vedotin
  • [Other-IDs] NLM/ PMC4709212 [Available on 01/01/17]
  • [Keywords] NOTNLM ; Adcetris / Brentuximab vedotin / European Medicines Agency / Hodgkin lymphoma / Systemic anaplastic large cell lymphoma
  •  go-up   go-down


6. Imamura R, Mouri F, Nomura K, Nakamura T, Oku E, Morishige S, Takata Y, Seki R, Osaki K, Hashiguchi M, Yoshimoto K, Ohshima K, Nagafuji K, Okamura T: Successful treatment of small cell variant anaplastic large cell lymphoma with allogeneic peripheral blood stem cell transplantation, and review of the literature. Int J Hematol; 2013 Jan;97(1):139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of small cell variant anaplastic large cell lymphoma with allogeneic peripheral blood stem cell transplantation, and review of the literature.
  • The small cell variant of anaplastic large cell lymphoma (ALCL) presents in a nearly identical manner to the more common ALK(+) primary ALCL, with the exception that it is more frequently associated with leukemic involvement, and the prognosis has been reported to be poor.
  • We report a 40-year-old Japanese male who was diagnosed with small cell variant ALCL with peripheral blood involvement stage IVB, age-adjusted international prognostic index 3.
  • Conventional cytogenetics of the bone marrow aspirate specimen showed abnormal metaphases with the following karyotype: 47, XY, +X, t(2;5)(p23;q35).
  • He underwent allogeneic peripheral blood stem cell transplantation from his HLA-DR1 locus mismatch sister.
  • We have identified a total of seven cases of small cell variant ALCL treated with allogeneic hematopoietic stem cell transplantation (HSCT) in the literature.
  • Allogeneic HSCT appears to represent a promising treatment option for small cell variant ALCL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Bone Marrow / pathology. Humans. Lymphocytes / pathology. Male. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome


7. Sevindik ÖG, Alacacıoğlu İ, Katgı A, Solmaz ŞM, Acar C, Pişkin Ö, Özcan MA, Demirkan F, Ündar B, Özsan GH: Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation. Case Rep Hematol; 2015;2015:425410
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal and neurological response with eculizumab in a patient with transplant associated thrombotic microangiopathy after allogeneic hematopoietic progenitor cell transplantation.
  • Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment.
  • We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function.
  • Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor cell transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25705530.001).
  • [ISSN] 2090-6560
  • [Journal-full-title] Case reports in hematology
  • [ISO-abbreviation] Case Rep Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4326272
  •  go-up   go-down


8. Gandolfi L, Pellegrini C, Casadei B, Stefoni V, Broccoli A, Tonialini L, Morigi A, Argnani L, Zinzani PL: Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. Oncologist; 2016 Dec;21(12):1436-1441
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
  • BACKGROUND: Brentuximab vedotin (BV) has shown high overall response rate in refractory/relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) with reported long-term response duration in clinical trials, but few data are available regarding its role in long-term outcomes in real life.
  • Among these cases, for all patients who underwent stem cell transplantation immediately after BV, the procedure was consolidative.
  • IMPLICATIONS FOR PRACTICE: Brentuximab vedotin (BV) has shown a high overall response rate in refractory/relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, with reported long-term response duration in clinical trials, whereas few data are available regarding its role in long-term outcomes in real life.
  • [MeSH-major] Hodgkin Disease / drug therapy. Immunoconjugates / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy


9. Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA: STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica; 2014 Jul;99(7):e105-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Disease Models, Animal. Hematologic Neoplasms / genetics. Mutation / genetics. Myeloproliferative Disorders / genetics. STAT3 Transcription Factor / genetics

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Oct 18;23(48):8017-23 [15489919.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):63-73 [9874564.001]
  • [Cites] Development. 2005 Mar;132(5):885-96 [15673569.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1515-23 [17951530.001]
  • [Cites] J Virol. 2010 Jan;84(2):993-1004 [19889776.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2852-63 [20154216.001]
  • [Cites] J Hematol Oncol. 2011;4(1):31 [21806788.001]
  • [Cites] Ann N Y Acad Sci. 2011 Dec;1246:34-40 [22236428.001]
  • [Cites] N Engl J Med. 2012 May 17;366(20):1905-13 [22591296.001]
  • [Cites] Blood. 2012 Oct 11;120(15):3048-57 [22859607.001]
  • [Cites] Mod Pathol. 2013 Oct;26(10):1329-37 [23599149.001]
  • [Cites] Haematologica. 2013 Nov;98(11):1748-52 [23872306.001]
  • [Cites] Leukemia. 2013 Nov;27(11):2244-7 [23563237.001]
  • [Cites] J Clin Oncol. 2013 Dec 20;31(36):4520-8 [24220563.001]
  • [CommentOn] Haematologica. 2013 Nov;98(11):1748-52 [23872306.001]
  • (PMID = 24837465.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor
  • [Other-IDs] NLM/ PMC4077094
  • [Keywords] NOTNLM ; B-cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma / CD30 / STAT3 / anaplastic large cell lymphoma / diffuse large B-cell lymphoma
  •  go-up   go-down


10. Vural F, Akad Soyer N, Özen P, Dönmez A, Ocakçı S, Saydam G, Çağırgan S, Tombuloğlu M: Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients. Turk J Haematol; 2010 Mar 5;27(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients.
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) of bone is a rare entity.
  • The most common histological subtype is diffuse large B cell lymphoma (DLBCL).
  • The major presenting symptoms are soft tissue swelling, bone pain and pathological fracture.
  • METHODS: We retrospectively analyzed the 18 patients (11 females, 7 males) with NHL of bone who were diagnosed and treated between 1995-2005.
  • The bone pain was the first symptom in all patients.
  • Tru-cut biopsy was performed for diagnosis in most of the cases.
  • Diagnosis in five patients (27.8%) required open biopsy.
  • Other histological subtypes were anaplastic large cell lymphoma (11.1%), Burkitt-like lymphoma (5.6%) and marginal zone lymphoma (5.6%).
  • Bone marrow involvement was determined in four patients (22.2%).
  • CONCLUSION: The treatment of bone lymphoma can be planned according to the stage and location of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265795.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down






Advertisement